4//SEC Filing
Laliberte Kevin 4
Accession 0001209191-19-040371
CIK 0001685071other
Filed
Jul 1, 8:00 PM ET
Accepted
Jul 2, 4:57 PM ET
Size
5.5 KB
Accession
0001209191-19-040371
Insider Transaction Report
Form 4
Laliberte Kevin
Sr. VP, Product Development
Transactions
- Sale
Common Stock
2019-07-01$14.17/sh−1,191$16,876→ 12,946 total
Footnotes (2)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person with the intent to cover withholding taxes in connection with the settlement of restricted stock units.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.04 to $14.39 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
Documents
Issuer
Dova Pharmaceuticals Inc.
CIK 0001685071
Entity typeother
Related Parties
1- filerCIK 0001709417
Filing Metadata
- Form type
- 4
- Filed
- Jul 1, 8:00 PM ET
- Accepted
- Jul 2, 4:57 PM ET
- Size
- 5.5 KB